REGENEREX PHARMA, INC. RGPX
OTC · stock · Pharmaceutical Preparations · website · IPO 2008-09-08
REGENEREX PHARMA, INC. financials (annual, from 10-K)
Bars are annual figures from 2014 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2014 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1,775 | $2,608 | — | — | — | $9,239 |
| Gross profit | — | — | — | — | -$244,917 | $896 | — | — | — | — |
| R&D expense | $662,479 | $2.4M | — | — | — | — | — | — | — | — |
| SG&A expense | $1.2M | $1.1M | — | — | — | — | — | — | — | — |
| Operating income | -$1.8M | -$3.5M | -$96,171 | -$126,267 | -$43,411 | -$77,003 | -$91,734 | -$49,451 | — | — |
| Interest expense | $320,047 | $80,638 | $66,788 | $59,063 | $42,905 | $28,658 | $778 | — | $3,556 | $10,438 |
| Income tax | -$2,717 | — | — | — | — | — | — | — | — | — |
| Net income | -$2.5M | -$3.5M | -$137,330 | -$195,591 | -$353,752 | $111,589 | -$93,579 | -$49,671 | $859,827 | -$981,181 |
| Operating cash flow | -$1.6M | -$457,548 | -$76,164 | -$69,922 | -$62,652 | -$291,179 | $47,059 | $36,122 | -$71,641 | -$255,264 |
| Cash & equivalents | $653,025 | $372 | $1,135 | $2,640 | $6,902 | $5,460 | $88,546 | $1,728 | $1,319 | $11,560 |
| Inventory | — | — | — | — | — | $246,691 | — | — | — | — |
| Total assets | $1.3M | $766,680 | $6,539 | $15,322 | $10,470 | $259,167 | $105,623 | $15,069 | $3,819 | $14,893 |
| Total liabilities | $5.4M | $4.8M | $1.1M | $1.0M | $845,496 | $740,441 | $475,308 | $336,175 | $799,214 | — |
| Shareholders' equity | -$4.2M | -$4.1M | -$1.1M | -$985,617 | -$835,026 | -$481,274 | -$369,685 | -$321,106 | -$795,395 | -$742,706 |
Growth · year-over-year · Revenue CAGR -56.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2014 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | -31.9% | — | — | — | — | — |
| Net income growth | — | — | — | — | -417.0% | — | — | -105.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001357878 · US · as of 2025-03-31. facts plus Stocktoria's own computed scores — not investment advice.